243 related articles for article (PubMed ID: 19798644)
1. Natalizumab: a double-edged sword?
DeAngelis LM
Ann Neurol; 2009 Sep; 66(3):262-3. PubMed ID: 19798644
[No Abstract] [Full Text] [Related]
2. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum.
Ransohoff RM
Ann Neurol; 2009 Sep; 66(3):259-61. PubMed ID: 19798722
[No Abstract] [Full Text] [Related]
3. Natalizumab and central nervous system lymphoma: no clear association.
Bozic C; LaGuette J; Panzara MA; Sandrock AW
Ann Neurol; 2009 Sep; 66(3):261-2. PubMed ID: 19798645
[No Abstract] [Full Text] [Related]
4. [Natalizumab in multiple sclerosis].
Rajda C; Bencsik K; Vécsei L;
Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
[No Abstract] [Full Text] [Related]
5. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Berger T; Deisenhammer F
N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16236749
[No Abstract] [Full Text] [Related]
6. Another complication of natalizumab treatment? Taking the challenge.
Goebels N; Kappos L
Ann Neurol; 2009 Sep; 66(3):264-6. PubMed ID: 19798646
[No Abstract] [Full Text] [Related]
7. [Natalizumab in multiple sclerosis: unclear patient benefits].
Schipper JP
Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
[TBL] [Abstract][Full Text] [Related]
8. Balancing risk and reward: the question of natalizumab.
Hauser SL; Johnston SC
Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
[No Abstract] [Full Text] [Related]
9. Primary central nervous system lymphoma in a patient treated with natalizumab.
Schweikert A; Kremer M; Ringel F; Liebig T; Duyster J; Stüve O; Hemmer B; Berthele A
Ann Neurol; 2009 Sep; 66(3):403-6. PubMed ID: 19798640
[TBL] [Abstract][Full Text] [Related]
10. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
[No Abstract] [Full Text] [Related]
11. Central nervous system lymphoma associated with natalizumab.
Na A; Hall N; Kavar B; King J
J Clin Neurosci; 2014 Jun; 21(6):1068-70. PubMed ID: 24373819
[TBL] [Abstract][Full Text] [Related]
12. Treating multiple sclerosis with natalizumab.
Iaffaldano P; Lucchese G; Trojano M
Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
[TBL] [Abstract][Full Text] [Related]
13. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
Major EO
N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
[No Abstract] [Full Text] [Related]
14. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Alvarez-Cermeño JC; Masjuan J; Villar LM
N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
[No Abstract] [Full Text] [Related]
15. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
16. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of multiple sclerosis].
Holmøy T; Harbo HF; Celius EG
Tidsskr Nor Laegeforen; 2010 May; 130(9):923; author reply 923. PubMed ID: 20453948
[No Abstract] [Full Text] [Related]
18. Natalizumab: bound to rebound?
Schiess N; Calabresi PA
Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
[No Abstract] [Full Text] [Related]
19. Reply to "'Thinking without thinking' about natalizumab and PML".
Houff S; Berger JR
J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
[No Abstract] [Full Text] [Related]
20. The return of natalizumab: weighing benefit against risk.
Goodin D
Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
